Cargando…

Mirabegron displays anticancer effects by globally browning adipose tissues

Metabolic reprogramming in malignant cells is a hallmark of cancer that relies on augmented glycolytic metabolism to support their growth, invasion, and metastasis. However, the impact of global adipose metabolism on tumor growth and the drug development by targeting adipose metabolism remain largel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Xiaoting, Sui, Wenhai, Mu, Zepeng, Xie, Sisi, Deng, Jinxiu, Li, Sen, Seki, Takahiro, Wu, Jieyu, Jing, Xu, He, Xingkang, Wang, Yangang, Li, Xiaokun, Yang, Yunlong, Huang, Ping, Ge, Minghua, Cao, Yihai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665320/ https://www.ncbi.nlm.nih.gov/pubmed/37993438 http://dx.doi.org/10.1038/s41467-023-43350-8

Ejemplares similares

Generation of mega brown adipose tissue in adults by controlling brown adipocyte differentiation in vivo
por: Du, Qiqiao, et al.
Publicado: (2022)

COVID-19 instigates adipose browning and atrophy through VEGF in small mammals
por: Jing, Xu, et al.
Publicado: (2022)

Brown-fat-mediated tumour suppression by cold-altered global metabolism
por: Seki, Takahiro, et al.
Publicado: (2022)

The effect of mirabegron on energy expenditure and brown adipose tissue in healthy lean South Asian and Europid men
por: Nahon, Kimberly J., et al.
Publicado: (2020)

Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors
por: Hosaka, Kayoko, et al.
Publicado: (2020)

Mirabegron: The most promising adipose tissue beiging agent
por: Bel, Jocelyn S., et al.
Publicado: (2021)

Mirabegron: a decade of study
por: Welk, Blayne
Publicado: (2020)

A miR-327–FGF10–FGFR2-mediated autocrine signaling mechanism controls white fat browning
por: Fischer, Carina, et al.
Publicado: (2017)

Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning
por: Seki, Takahiro, et al.
Publicado: (2018)

Correction: Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning
por: Seki, Takahiro, et al.
Publicado: (2020)

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice
por: Kim, Seo-Yeon, et al.
Publicado: (2023)

Disruption of the Clock Component Bmal1 in Mice Promotes Cancer Metastasis through the PAI‐1‐TGF‐β‐myoCAF‐Dependent Mechanism
por: Wu, Jieyu, et al.
Publicado: (2023)

Inaccuracies in the recently published review on mirabegron
por: Siddiqui, Emad
Publicado: (2013)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Serum sickness–like reaction associated with mirabegron
por: Tan, Marcus G., et al.
Publicado: (2019)

Distinct Conformations of Mirabegron Determined by MicroED
por: Lin, Jieye, et al.
Publicado: (2023)

Perivascular localized cells commit erythropoiesis in PDGF‐B‐expressing solid tumors
por: Hosaka, Kayoko, et al.
Publicado: (2023)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

The combined effect of metformin and mirabegron on diet‐induced obesity
por: Zhao, Xin‐Yuan, et al.
Publicado: (2023)

Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
por: Scandura, Carmen, et al.
Publicado: (2020)

Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
por: Yamanishi, Tomonori, et al.
Publicado: (2020)

Human mediastinal adipose tissue displays certain characteristics of brown fat
por: Cheung, L, et al.
Publicado: (2013)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Respiratory dysfunction following initiation of mirabegron: A case report
por: Malsin, Elizabeth S., et al.
Publicado: (2019)

The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors
por: Dehvari, Nodi, et al.
Publicado: (2020)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
por: Shaw, Christina, et al.
Publicado: (2023)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
por: Makhani, Asad, et al.
Publicado: (2020)

Symptom improvement with mirabegron treatment is associated with urobiome changes in adult women
por: Halverson, Thomas, et al.
Publicado: (2022)

Selectivity and Maximum Response of Vibegron and Mirabegron for β(3)-Adrenergic Receptors
por: Brucker, Benjamin M., et al.
Publicado: (2022)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
por: Sartori, Luisa Gracio Ferreira, et al.
Publicado: (2023)

Switching harmful visceral fat to beneficial energy combustion improves metabolic dysfunctions
por: Yang, Xiaoyan, et al.
Publicado: (2017)

A phase II dose-ranging study of mirabegron in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2013)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
por: Xu, Yankai, et al.
Publicado: (2017)

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience
por: Allison, Sara J., et al.
Publicado: (2018)

Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy
por: Kovács, Zsuzsanna Z. A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_805cq9aehtsvepie286u4u2q9f